Unity Biotechnology Rakes In $116M From Investors
Unity Biotechnology Inc., a privately held company tasked with preventing and reversing aging related diseases, on Thursday said that it closed a Series B funding round, securing $116 million in financing...To view the full article, register now.
Already a subscriber? Click here to view full article